Hemophilia B Stocks List
Related Industries: Biotechnology
Related Stock Lists:
Acute Intermittent Porphyria
Adeno Associated Virus
Alipogene Tiparvovec
Applied Genetics
Biology
Biopharmaceutical
Clinical Development
Disease
Gene Delivery
Gene Therapy
Genetics
Glybera
Hemophilia
Lipase
Lipoprotein
Lipoprotein Lipase Deficiency
Metabolic Disease
Parkinson's Disease
Treatment Of Hemophilia
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
WDNA | C | WisdomTree BioRevolution Fund | 0.58 | |
BBC | C | Virtus LifeSci Biotech Clinical Trials ETF | 0.47 | |
GNOM | D | Global X Genomics & Biotechnology ETF | 0.4 | |
BIS | D | ProShares UltraShort Nasdaq Biotechnology | 0.35 | |
IDNA | C | iShares Genomics Immunology and Healthcare ETF | 0.28 |
Compare ETFs
Related Industries:
Biotechnology
Related Stock Lists:
Acute Intermittent Porphyria
Adeno Associated Virus
Alipogene Tiparvovec
Applied Genetics
Biology
Biopharmaceutical
Clinical Development
Disease
Gene Delivery
Gene Therapy
Genetics
Glybera
Hemophilia
Lipase
Lipoprotein
Lipoprotein Lipase Deficiency
Metabolic Disease
Parkinson's Disease
Treatment Of Hemophilia
- Hemophilia B
Haemophilia B is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (haemophilia A).
Haemophilia B was first recognized as a distinct disease entity in 1952. It is also known by the eponym Christmas disease, named after Stephen Christmas, the first patient described with haemophilia B. In addition, the first report of its identification was published in the Christmas edition of the British Medical Journal.
Recent Comments
- TraderMike on Market Recap for Friday, March 8, 2024
- Don_Marat on Market Recap for Friday, March 8, 2024
- TraderMike on Trades of the Week: Feb 12 - Feb 16, 2024
- Cos3 on Trades of the Week: Feb 12 - Feb 16, 2024
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
From the Blog
Featured Articles